Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 301–400 of 1,001
Ji, X., Tong, W., Liu, Z., & Shi, T. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00600 · Cited by 69
Eiger, D., Ponde, N. F., Agbor‐Tarh, D., Moreno‐Aspitia, A., Piccart, M. J., Hilbers, F., Werner, O., Chumsri, S., Dueck, A. C., Kroep, J. R., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0786-x · Cited by 63
Targeted therapy for gastric cancer: Current status and future directions (Review)
Yuan, D., Zhu, Z.-X., Zhang, X., & Liu, J. (2015) · Oncology Reports · doi:10.3892/or.2015.4528 · Cited by 66
Cheng, J., Holland‐Letz, T., Wallwiener, M., Surowy, H., Ćuk, K., Schott, S., Trumpp, A., Pantel, K., Sohn, C., Schneeweiß, A., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4666-5 · Cited by 69
Updates in the Evaluation and Management of Breast Cancer
O'Sullivan, C. C., Loprinzi, C. L., & Haddad, T. C. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.03.025 · Cited by 76
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Kaito, A., Kuwata, T., Tokunaga, M., Shitara, K., Sato, R., Akimoto, T., & Kinoshita, T. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i15.1964 · Cited by 68
Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A. H., Bachelot, T., Chan, S. Y. T., Han, H. S., Jerusalem, G., Urban, P., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4596-7 · Cited by 66
Araki, K., Ito, Y., Fukada, I., Kobayashi, K., Miyagawa, Y., Imamura, M., Kira, A., Takatsuka, Y., Egawa, C., Suwa, H., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4888-2 · Cited by 65
Uijen, M. J. M., Lassche, G., Grunsven, A. C. H. V. E., Tada, Y., Verhaegh, G. W. C. T., Schalken, J. A., Driessen, C. M. L., & van Herpen, C. M. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102069 · Cited by 62
Addressing the challenges of applying precision oncology
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0032-z · Cited by 62
Liu, Y., Xu, J., Choi, H. H., Han, C., Fang, Y., Li, Y., der Jeught, K. V., Xu, H., Zhang, L., Frieden, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07264-0 · Cited by 64
RetractedCurrent Trends in the Treatment of HR+/HER2+ Breast Cancer
Kay, C., Martínez-Pérez, C., Meehan, J., Gray, M., Webber, V. L., Dixon, J. M., & Turnbull, A. (2021) · Future Oncology · doi:10.2217/fon-2020-0504 · Cited by 65
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
Franchina, M., Pizzimenti, C., Fiorentino, V., Martini, M., Ricciardi, G. R. R., Silvestris, N., Ieni, A., & Tuccari, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612795 · Cited by 70
Cavallaro, P. A., Santo, M. D., Belsito, E. L., Longobucco, C., Curcio, M., Morelli, C., Pasqua, L., & Leggio, A. (2023) · Nanomaterials · doi:10.3390/nano13172476 · Cited by 66
Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy
Horton, J. K., Jagsi, R., Woodward, W. A., & Ho, A. Y. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.08.025 · Cited by 65
Bouwer, N. I., Jager, A., Liesting, C., Kofflard, M. J. M., Brugts, J. J., Kitzen, J. J. E. M., Boersma, E. H., & Levin, M. (2020) · The Breast · doi:10.1016/j.breast.2020.04.005 · Cited by 65
da Costa, D. C. F., Rangel, L. P., Quarti, J., Santos, R. A., Silva, J. L., & Fialho, E. (2020) · Molecules · doi:10.3390/molecules25153531 · Cited by 66
Wilding, B., Scharn, D., Böse, D., Baum, A., Santoro, V., Chetta, P., Schnitzer, R., Botesteanu, D., Reiser, C., Kornigg, S., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00412-y · Cited by 65
A systemic review of taxanes and their side effects in metastatic breast cancer
Lai, J., Chao, T., Liu, C., Huang, C., & Tseng, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940239 · Cited by 63
Orcutt, X., Chen, K., Mamtani, R., Long, Q., & Parikh, R. B. (2025) · Nature Medicine · doi:10.1038/s41591-024-03352-5 · Cited by 66
Simone, B. A., Dan, T., Palagani, A., Jin, L., Han, S. Y., Wright, C. M., Savage, J. E., Gitman, R., Lim, M. K., Palazzo, J., et al. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1160982 · Cited by 60
Adjuvant trastuzumab: a 10-year overview of its benefit
Lambertini, M., Ponde, N. F., Solinas, C., & de Azambuja, E. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1264876 · Cited by 63
Advances in the management of HER2-positive early breast cancer
Baselga, J. M., Coleman, R. E., Cortés, J., & Janni, W. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.001 · Cited by 72
Self-citationTrastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
Nowsheen, S., Aziz, K., Park, J. Y., Lerman, A., Villarraga, H. R., Ruddy, K. J., & Herrmann, J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008637 · Cited by 60
Shao, Y., Yu, Y., Luo, Z., Guan, H., Zhu, F., He, Y., Chen, Q., Liu, C., Nie, B., & Liu, H. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12369-4 · Cited by 57
Tabernero, J. M., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Siddiqui, A., Heeson, S., Kiermaier, A. C., Macharia, H., Restuccia, E., et al. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01335-4 · Cited by 64
Self-citationde Vries, E. G. E., Rüschoff, J., Lolkema, M. P., Tabernero, J. M., Gianni, L., Voest, E. E., de Groot, D. J. A., Castellano, D., Erb, G., Naab, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5893 · Cited by 61
Genomic Disparities in Breast Cancer among Latinas
Lynce, F. C., Graves, K. D., Jandorf, L. H., Ricker, C. N., Castro, E., Moreno, L., Augusto, B. M., Fejerman, L., & Vadaparampil, S. T. (2016) · Cancer Control · doi:10.1177/107327481602300407 · Cited by 60
Ulaner, G. A., Castillo, R., Wills, J., Gönen, M., & Goldman, D. A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3709-1 · Cited by 57
Costa, R. L. B., Soliman, H. H., & Czerniecki, B. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.005 · Cited by 56
Chia, S., Bedard, P. L., Hilton, J. F., Amir, E., Gelmon, K. A., Goodwin, R. A., Villa, D. R., Cabanero, M., Tu, D., Tsao, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0321 · Cited by 61
M.S, D. M. B., Phillips, G. S., Geisler, A. N., Trelles, S., Markova, A., Noor, S. J., Quigley, E. A., Haliasos, H. C., Moy, A. P., Schram, A. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.016 · Cited by 58
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Gaborit, N., Lindzen, M., & Yarden, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102809 · Cited by 60
Yu, A. F., Manrique, C. R., Pun, S. C., Liu, J. E., Mara, E., Fleisher, M., Patil, S. N., Jones, L. W., Steingart, R. M., Hudis, C. A., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0321 · Cited by 56
Targeted Therapy in Brain Metastases: Ready for Primetime?
Venur, V. A., & Ahluwalia, M. S. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100006 · Cited by 61
Bonotto, M., Gerratana, L., Maïo, M. D., Angelis, C. D., Cinausero, M., Moroso, S., Milano, M., Stanzione, B., Gargiulo, P., Iacono, D., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.10.021 · Cited by 59
Kodumudi, K. N., Ramamoorthi, G., Snyder, C., Basu, A. B., Jia, Y., Awshah, S., Beyer, A., Wiener, D. A., Lam, L., Zhang, H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01939 · Cited by 55
Yao, H., Yan, M., Tong, Z., Wu, X., Ryu, M., Park, J., Kim, J. H., Zhong, Y., Zhao, Y., Voskoboynik, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02044 · Cited by 61
Chen, X., Liu, P., Wang, Q., Li, Y., Li, F., Fu, H., Zhu, J., Chen, Z., Zhu, W., Xie, C., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.012 · Cited by 55
Jagosky, M. H., & Tan, A. R. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s176514 · Cited by 66
Martin, M., Fumoleau, P., Dewar, J. A., Albanell, J., Limentani, S. A., Campone, M., Chang, J. C., Patre, M., Strasak, A. M., de Haas, S. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw157 · Cited by 54
Self-citationAccess to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab
Barrios, C. H., Reinert, T., & Werutsky, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.898 · Cited by 54
Xu, B., Li, W., Zhang, Q., Shao, Z., Li, Q., Wang, X., Li, H., Sun, T., Yin, Y., Zheng, H. Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05728-w · Cited by 56
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
Barroso‐Sousa, R., & Tolaney, S. M. (2021) · BioDrugs · doi:10.1007/s40259-021-00472-z · Cited by 57
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
Holloway, R. W., & Marignani, P. A. (2021) · Cancers · doi:10.3390/cancers13122922 · Cited by 61
Xuhong, J., Qi, X., Tang, P., Fan, L., Chen, L., Zhang, F., Tan, X., Yan, W., Zhong, L., He, C., et al. (2020) · The Oncologist · doi:10.1002/onco.13546 · Cited by 53
Phillips, G. D. L., Li, G., Guo, J., Yu, S., Fields, C. T., Lee, G., Zhang, D., Dragovich, P. S., Pillow, T. H., Wei, B. Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44533-z · Cited by 61
Henry, K. E., Ulaner, G. A., & Lewis, J. S. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.02.001 · Cited by 54
Rampogu, S. D., Son, M., Baek, A., Park, C., Rana, R. M., Zeb, A., Saravanan, P., & Lee, K. W. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.04.002 · Cited by 54
Oxidative stress: therapeutic approaches for cervical cancer treatment
Silva, G. Á. F., Nunes, R. A. L., Morale, M. G., Boccardo, E., Aguayo, F., & Termini, L. (2018) · Clinics · doi:10.6061/clinics/2018/e548s · Cited by 63
Modi, N. D., Tan, E., Rowland, A., Koczwara, B., Abuhelwa, A. Y., Kichenadasse, G., McKinnon, R. A., Wiese, M. D., Sorich, M. J., & Hopkins, A. M. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00241-9 · Cited by 57
Tobin, N. P., Foukakis, T., Petris, L. D., & Bergh, J. C. S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12429 · Cited by 59
Mueller, S. K., Haderlein, M., Lettmaier, S., Agaimy, A., Haller, F., Hecht, M., Fietkau, R., Iro, H., & Mantsopoulos, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030720 · Cited by 52
Tsao, L.-C., Crosby, E. J., Trotter, T. N., Wei, J.-P., Wang, T., Yang, X. Y., Summers, A. N., Lei, G., Rabiola, C. A., Chodosh, L. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155636 · Cited by 57
Arpino, G., de la Haba-Rodríguez, J., Ferrero, J.-M., Placido, S. D., Osborne, C. K., Klingbiel, D., Revelant, V., Wohlfarth, C., Poppe, R., Rimawi, M. F., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1092 · Cited by 53
Self-citationTreatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature
Martínez, M. T., Fidalgo, J. A. P., Martín-Martorell, P., Cejalvo, J. M., Pons, V., Bermejo, B., Martín, M., Albanell, J., & Lluch, A. M. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.011 · Cited by 60
Pivot, X. B., Verma, S., Fallowfield, L. J., Müller, V., Lichinitser, M., Jenkins, V. A., Muñoz, A. S., Machackova, Z., Osborne, S., & Gligorov, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.019 · Cited by 56
Hölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Kiechle, M. B., Mahner, S., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2428-0 · Cited by 53
Collins, D. M., Jacob, W., Cejalvo, J. M., Ceppi, M., James, I., Hasmann, M., Crown, J. P., Cervantes, A. M. R., Weisser, M., & Bossenmaier, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177331 · Cited by 56
Tirino, G., Pompella, L., Petrillo, A., Laterza, M. M., Pappalardo, A., Caterino, M., Orditura, M., Ciardiello, F., Galizia, G., & Vita, F. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092659 · Cited by 53
Pegram, M. D., Miles, D. W., Tsui, C. K., & Zong, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1976 · Cited by 53
Conte, B., Fabi, A., Poggio, F. B., Blondeaux, E., Dellepiane, C., D’Alonzo, A., Buono, G., Arpino, G., Magri, V., Naso, G., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.09.001 · Cited by 52
CSNK2 in cancer: pathophysiology and translational applications
Strum, S. W., Gyenis, L., & Litchfield, D. W. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01616-2 · Cited by 65
Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
Gale, M., Li, Y., Cao, J. P., Liu, Z. Z., Holmbeck, M. A., Zhang, M., Lang, S. M., Wu, L., DoCarmo, M., Gupta, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3985 · Cited by 52
Vo, D. T., Karanam, N. K., Ding, L., Saha, D., Yordy, J. S., Giri, U. P., Heymach, J. V., & Story, M. D. (2019) · Neoplasia · doi:10.1016/j.neo.2019.06.004 · Cited by 54
Siemer, S., Bauer, T. A., Scholz, P., Breder, C., Fenaroli, F., Harms, G. S., Dietrich, D., Dietrich, J., Rosenauer, C., Barz, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c08632 · Cited by 51
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Metzger, O., Mandrekar, S. J., Goel, S., Gligorov, J., Lim, E., Ciruelos, E., Loibl, S., Dockter, T., González, X., Francis, P. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2511218 · Cited by 62
Self-citationMorikawa, A., de Stanchina, E., Pentsova, E. I., Kemeny, M. M., Li, B. T., Tang, K., Patil, S. N., Fleisher, M., Poznak, C. H. V., Norton, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3502 · Cited by 50
A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead
Bishayee, A., & Block, K. I. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.002 · Cited by 50
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
Schramm, A., de Gregorio, N., Widschwendter, P., Fink, V., & Huober, J. (2015) · Breast Care · doi:10.1159/000431029 · Cited by 49
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M. D., Guardino, E., Althaus, B., Lu, D., Strasak, A. M., & ELIAS, A. D. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0691-7 · Cited by 49
Kong, A. H., Rea, D. W., Ahmed, S. I., Beck, J. T., López‐López, R., Biganzoli, L., Armstrong, A. C., Aglietta, M., Alba, E., Campone, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8974 · Cited by 49
Self-citationTargeted Therapy for Cancer in the Genomic Era
Afghahi, A., & Sledge, G. W. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000135 · Cited by 55
Brain, E. G. C., Caillet, P., de Glas, N. A., Biganzoli, L., Cheng, K. K. F., Lago, L. D., & Wildiers, H. P. M. W. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.06.004 · Cited by 53
Bone Metastasis: Current State of Play
Turpin, A., Duterque‐Coquillaud, M., & Vieillard, M.-H. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.10.012 · Cited by 61
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
Ferrando‐Díez, A., Felip, E., Pous, A., Bergamino, M. A., & Vila, M. M. (2022) · Cancers · doi:10.3390/cancers14143305 · Cited by 51
Bergeron, A., Bertaut, A., Beltjens, F., Charon‐Barra, C., Amet, A., Jankowski, C., Desmoulins, I., Ladoire, S., & Arnould, L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02287-x · Cited by 58
Razumienko, E. J., Chen, J. C., Cai, Z., Chan, C., & Reilly, R. M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162339 · Cited by 51
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy
Han, C. H., & Brastianos, P. K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00230 · Cited by 53
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino, A. R. B., Amaro, C. P., & Verma, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918818346 · Cited by 52
Recent Developments of Systemic Chemotherapy for Gastric Cancer
Arai, H., & Nakajima, T. E. (2020) · Cancers · doi:10.3390/cancers12051100 · Cited by 51
Tesch, M. E., & Gelmon, K. A. (2020) · Drugs · doi:10.1007/s40265-020-01411-y · Cited by 55
Ikesue, H., Mouri, M., Tomita, H., Hirabatake, M., Ikemura, M., Muroi, N., Yamamoto, S., Takenobu, T., Tomii, K., Kawakita, M., et al. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06018-x · Cited by 48
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
Pellerino, A., Brastianos, P. K., Rudà, R., & Soffietti, R. (2021) · Cancers · doi:10.3390/cancers13122888 · Cited by 50
Harano, K., Lei, X. J., Gonzalez-Angulo, A. M., Murthy, R. K., Valero, V., Mittendorf, E. A., Ueno, N. T., Hortobágyi, G. N., & Chávez‐MacGregor, M. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3933-6 · Cited by 47
Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer
Liu, X., Zhang, X., Shao, Z., Zhong, X., Ding, X., Wu, L., Chen, J., He, P., Cheng, Y., Zhu, K., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01689-w · Cited by 49
Review on the Applications and Molecular Mechanisms ofXihuangPill in Tumor Treatment
Guo, Q., Lin, J., Liu, R., Gao, Y., He, S., Xu, X., Hua, B., Li, C., Hou, W., Zheng, H., et al. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/854307 · Cited by 51
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
Murthy, P., Kidwell, K., Schott, A. F., Merajver, S. D., Griggs, J. J., Smerage, J. B., Poznak, C. H. V., Wicha, M. S., Hayes, D. F., & Henry, N. L. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3705-3 · Cited by 47
Nowsheen, S., Viscuse, P. V., O'Sullivan, C. C., Sandhu, N. P., Haddad, T. C., Blaes, A. H., Klemp, J. R., Nhola, L. F., Herrmann, J., & Ruddy, K. J. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0249-4 · Cited by 50
Ghassami, E., Varshosaz, J., Jahanian‐Najafabadi, A., Minaiyan, M., Rajabi, P., & Hayati, E. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s152474 · Cited by 48
Extreme oncoplastic conservation is a safe new alternative to mastectomy
Pearce, B., Fiddes, R. N., Paramanathan, N., Chand, N., Laws, S., & Rainsbury, R. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.09.004 · Cited by 48
Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
Eniu, A. E., Cherny, N. I., Bertram, M., Thongprasert, S., Douillard, J.-Y., Bricalli, G., Vyas, M., & Trapani, D. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000483 · Cited by 51
Story, M. D., & Durante, M. (2018) · Medical Physics · doi:10.1002/mp.13064 · Cited by 49
Boafo, G. F., Shi, Y., Xiao, Q., Magar, K. T., Zoulikha, M., Xing, X., Teng, C., Emmanuel, B., Li, X., Jiang, X., et al. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.04.033 · Cited by 46
Botticelli, A., Caputo, R., Scagnoli, S., Pisegna, S., Laurentiis, M. D., Curigliano, G., Lambertini, M., Pantano, F., Palazzo, A., Paris, I., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad308 · Cited by 52
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Waks, A. G., Martínez‐Sáez, O., Tarantino, P., Brasó‐Maristany, F., Pascual, T., Cortés, J., Tolaney, S. M., & Prat, A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00939-2 · Cited by 56
Self-citationGallego‐Yerga, L., Posadas, I., de la Torre, C., Ruiz-Almansa, J., Sansone, F., Mellet, C. O., Casnati, A., Fernández, J. M. G., & Ceña, V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00249 · Cited by 50
Lux, M. P., Nabieva, N., Hartkopf, A. D., Huober, J., Volz, B., Taran, F., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., et al. (2018) · Cancers · doi:10.3390/cancers11010010 · Cited by 47
Garrison, L. P., Babigumira, J. B., Tournier, C., Goertz, H., Lubinga, S. J., & Perez, E. A. (2019) · Value in Health · doi:10.1016/j.jval.2018.11.014 · Cited by 48
Oligometastatic breast cancer: where are we now and where are we headed?—a narrative review
Kent, C. L., McDuff, S. G. R., & Salama, J. K. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1128 · Cited by 48
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.